EBVaGC, a molecular subtype classified by TCGA that accounts for approximately 5% of GC cases, has distinct clinicopathological and genetic features, and EBV infection and a lack of SALL4 may mark a group of GC patients with a better prognosis (Yang et al., 2019). This evidence concerns the gene SALL4 and gastric cancer.